[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC

We read with great interest the article by Val érie Vilgrain and colleagues,1 reporting the results of a randomised controlled trial comparing sorafenib with selective internal radiotherapy (SIRT) in patients with locally advanced or intermediate-stage hepatocellular carcinoma (HCC) after unsuccessful transarterial chemoembolisation, and congra tulate the authors for their excellent work. Compared with sorafenib, SIRT did not improve overall or progression-free survival; however, it did significantly increase tumour response, reduce incidence of adverse events, and improve the quality of life.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Correspondence Source Type: research